RxDoctor Payments Data

Emily Scholl, PA

Physician Assistant · Chicago, ILNPI 1962148411

Payments from drug & device makers

$3,224in general payments, 2019–2025

Across 147 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$385
  • Antares Pharma, Inc.$382
  • Sumitomo Pharma America, Inc.$268
  • C. R. Bard, Inc. & Subsidiaries$228
  • Bayer$195
  • Halozyme Inc$195
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$3,11397%
  • Education$943%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,224 in reported general payments places this provider in the 90th percentile of 3,912 physician assistant providers in Illinois.

See all physician assistant providers in Illinois

Medicare billing

Part B allowed, 2024
$10,169
Medicare patients
80
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron137$147,604
MyrbetriqMirabegron35$29,179
XyostedTestosterone Enanthate24$18,048
Methenamine Hippurate66$3,319
Tamsulosin Hcl245$3,266
Estradiol28$1,651
Finasteride125$1,621
Potassium Citrate ErPotassium Citrate14$1,297
Testosterone Cypionate30$1,157
Alfuzosin Hcl ErAlfuzosin Hcl30$944
Cephalexin176$471
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$456
Oxybutynin Chloride ErOxybutynin Chloride13$339
Ciprofloxacin Hcl60$303
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$268$147,604137 claims
Astellas Pharma US IncMyrbetriq$109$29,17935 claims
Antares Pharma, Inc.Xyosted$382$18,04824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,912 physician assistant providers in Illinois.

Other physician assistant in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →